Nasdaq auph.

Dec 4, 2023 · AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ... Caiaimage/Paul Bradbury. Aurinia Pharmaceuticals ( NASDAQ: AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. The pharma has retained JP Morgan as ...Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...Nov 24, 2021 · Every investor in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ... Aurinia Pharmaceuticals (NASDAQ: AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its ...

1 day ago · Nasdaq Auph, also known as Aurinia Pharmaceuticals, is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases. With a strong pipeline of innovative drugs and a commitment to improving patients’ lives, Nasdaq Auph has garnered attention from investors and industry experts alike. Aurinia Pharmaceuticals ( AUPH 1.10%), a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1 ...SVB Leerink waxed optimistic on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), saying the stock could rally 250% if late-stage trial data for the company's kidney inflammation treatment shows a ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is certainly one of the US-listed biotech stocks with significant upside potential as this Canadian biotechnology company, having bolstered its patent ...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open.The consensus EPS Estimate is -$0.33 and the consensus...Oct 30, 2023 · We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ... NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) value has fallen 11% in the last week, but insiders who sold US$32m worth of stock over the last year have had less success. Insiders would probably ...

We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ...

Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...

Aurinia Pharmaceuticals AUPH stock was up about 11% on Tuesday after the company announced that the United States Patent and Trademark Office (USPTO) issued a new and refined method-of-use patent ...The public float for AUPH is 130.54M, and at present, short sellers hold a 13.23% of that float. The average trading volume of AUPH on November 20, 2023 was 1.70M shares. AUPH) stock’s latest price update. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has increased by 3.08 compared to its previous closing price of 8.60.Aurinia Pharmaceuticals Price Performance Shares of NASDAQ:AUPH opened at $9.06 on Monday. Aurinia Pharmaceuticals Inc. has a twelve month low of …In a recent SEC filing, Russell Investments Group Ltd. revealed that it had added to its portfolio with a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP). The biotechnology company has become an attractive option for investors due to their focus on developing and commercializing therapies for diseases with unmet …Dec 4, 2023 · December 4, 2023. Business. B. Riley Financial Inc (NASDAQ:RILY) has a beta value of 1.57 and has seen 0.91 million shares traded in the recent trading session. The company, currently valued at $723.52M, closed the recent trade at $23.66 per share which meant it gained $3.51 on the day or 17.42% during that session.

Shares of NASDAQ:AUPH opened at $9.06 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -17.09 and a beta of 1.25. The company has a debt-to-equity ratio of 0.18, a current ...AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis.Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% UpsideIn trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ...Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...

Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).The firm owned 279,300 shares of the biotechnology company’s stock after acquiring an …Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...

Rhumbline Advisers raised its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 3.2% in the 2nd quarter, according to the company in its most recent ...(RTTNews) - Today's Daily Dose brings you news about the layoff in Allena Pharma; the positive phase III trial results of Aurinia Pharma's lupus drug; stock offerings of Millendo Therapeutics and ...To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not including dividends) in the same ...ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.Amounts are expressed in U.S. dollars. Net product revenue was $40.8 million for the three months ended …Jun 30, 2023 · NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (2.09%) $0.18. Current Price. ... (AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares ... AUPH Aurinia Pharmaceuticals Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update ...Aurinia Pharmaceuticals AUPH shares ended the last trading session 5.7% higher at $9.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...Aurinia Pharmaceuticals 22.3 mln share stock offering priced at $6.75, 36% below Monday's closing price. Mar. 14, 2017 at 8:04 a.m. ET by Tomi Kilgore.

Aurinia Pharmaceuticals (NASDAQ: AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its ...

Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, …Aurinia Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. AUPH updated stock price target summary.The public float for AUPH is 130.54M, and currently, shorts hold a 13.23% of that float. The average trading volume for AUPH on November 16, 2023 was 1.69M shares. AUPH) stock’s latest price update. The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has dropped by -0.12 compared to previous close of 8.17.December 4, 2023. Technologies. Vertex Energy Inc (NASDAQ:VTNR) has a beta value of 1.68 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $348.79M, closed the recent trade at $3.73 per share which meant it gained $0.11 on the day or 3.04% during that session.AUPH opened at $9.06 on Friday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.07 and a 1 year high of $12.43. The stock’s 50 day simple moving average is $7.93 and its 200 day simple ...Jan 8, 2022 · With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ... Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ...Nov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... Aurinia Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. AUPH updated stock price target summary.See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. AUPH's current price target is …About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

Sep 27, 2023 · It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ... Aldeyra Therapeutics Inc (NASDAQ:ALDX) has a beta value of 1.43 and has seen 0.58 million shares traded in the recent trading session. The company, currently valued at $177.64M, closed the recent trade at $3.02 per share which meant it gained $0.16 on the day or 5.59% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …Skip to main content. Market Activity. ->. Funds + ETFs. After-Hours Quotes. See All Market Activity->.Instagram:https://instagram. exxonmobil dividendscart tickerlamb wessoncobra vs private insurance To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not including dividends) in the same ... fang dividend historyreasonable motorcycle insurance (NASDAQ: AUPH) Aurinia Pharmaceuticals currently has 143,608,164 outstanding shares. With Aurinia Pharmaceuticals stock trading at $8.23 per share, the total value of Aurinia Pharmaceuticals stock (market capitalization) is $1.18B .It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ... quantumscape stock forecast 2025 Which Aurinia Pharmaceuticals insiders have been selling company stock? The following insiders have sold AUPH shares in the last 24 months: David R.W. Jayne ($98,333.58), Joseph M Miller ($100,986.24), Joseph P Hagan ($2,877.76), Peter Greenleaf ($292,785.00), and Stephen P Robertson ($173,453.88). How much insider selling is …What happenedAurinia Pharmaceuticals (NASDAQ: AUPH), a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The ...